March 29, 2021 - Braunschweig anti-cancer antibody in clinical trials in the USA: New Drug Grips Tumor Cells With Two Arms.
The first patients with advanced tumors have been treated with the novel antibody-based drug M1231 in a clinical trial in the USA. It uses an invention of the Technical University of Braunschweig: The team of Professor Stefan Dübel, head of the Department of Biotechnology, discovered a human antibody that targets tumor cells and developed it over many years. This antibody is now part of a complex novel compound against difficult-to-treat cancers that is undergoing clinical testing by the pharmaceutical company Merck.
The Department of Biotechnology is one of the divisions of the Institute for Biochemistry, Biotechnology and Bioinformatics. Founded in 1972, it was a key player in establishing biotechnology research in Braunschweig, and established the first dedicated Biotechnology curriculum at a german university.
In 2002, Prof. Dr. Stefan Dübel joined the Department as director, adding a new research focus on Molecular Engineering, in particular Human Antibody Engineering and Phage Display. The Department quickly became the home to some of the world's largest and most successful academic human monoclonal antibody libraries, while the well established research focus on Biochemical Engineering, led by Prof. Dr. Siegmund Lang and Prof. Dr. Udo Rau, continued its succesful development. A particular focus on the fight against infectious diseasese has been established by Prof. Dr. Michael Hust.
Today, with fundamental and applied research topics spanning a very broad range including molecular and cell biology, infection biology. intrabodies, biomarker and drug discovery, vaccine development, synthetic biology, in vitro evolution, the Department is well-endowed to embark into the challenges of cutting egde biotechnology research of the future. A long list of successful technology transfers including developmet of clinical stage anti-cancer and anti-virus antibodies proves the significance of our research for society, further complemented by avoiding animal experiments for antibody generation and providing new ways to develop designer medications for the 21 century.
Department of Biotechnology Institute for Biochemistry, Biotechnology and Bioinformatics Technical University of Braunschweig
By train: For all railway connections, see Deutsche Bahn. Exit Braunschweig main station. Just in front, slightly left, are bus platforms. Take the bus line 419 (direction: Hauptbahnhof, leaves about every 10 min at workdays), exit at Gliesmaroder Straße (5th stop) or Bültenweg (6th stop) (klick map for larger version). Bus connection details: http://www.braunschweiger-verkehrs-ag.de
By air: Nearest airport with scheduled service is Hannover (HAJ). Best way of transfer to Braunschweig is to take an airport shuttle (45 min, needs reservation) or train (ca. 1,5 h, change of train at Hannover main station). In some cases, particular from overseas, it may be faster to fly into Frankfurt (FRA) and take the comfortable ICE train to Braunschweig (3,5 hours); most ICE connections are via Frankfurt main railway station. From Berlin's airports it takes about 2,5h by train or car - you may take a taxi to the Berlin main station and use the ICE train (1,3h) to Braunschweig. For all railway connections, see Deutsche Bahn.
For visitors using their own aircraft, Braunschweig-Wolfsburg airport (IATA: BWE, ICAO: EDVE) is located 7km (15 min by Taxi) from the Institute. There are no scheduled public passenger services. Position N52°19.16' E10°33.53' in 297ft MSL, TORA2300m, ILS RWY 26, EGNOS 08/26, NDB 08/26, METAR/TAF (all informations not for navigation)